Development of High Throughput Quantitative PCR Assays for RSV

目前，没有针对呼吸道合胞病毒（RSV）的疫苗，治疗选择也有限。在RSV的标准化和吞吐量潜力方面，中和试验的改进将促进新疫苗和治疗方法的开发。该合同支持开发高通量定量PCR检测人类呼吸道合胞病毒（亚型A和B）的中和抗体。

Currently, there are no vaccines available for Respiratory Syncytial Virus (RSV), and treatment options are limited. Improvements in neutralization assays, in terms of standardization and throughput potential, for RSV would facilitate the development of novel vaccines and therapeutics. This contract supports the development of high throughput quantitative PCR assays to detect neutralizing antibody to human respiratory syncytial viruses (subtypes A and B).